LIEGE, BELGIUM--(Marketwire - October 29, 2012) - In order to continue receiving MDxHealth's press releases or other Company information, please click on the link below to select the type and language of the press releases offered.
www.mdxhealth.com then press the 'subscribe' link at the top right of the page.
We thank you in advance for the interest shown towards our Company.
MDxHealth (NYSE Euronext: MDXH) (EURONEXT AMSTERDAM: MDXH) (EURONEXT BRUSSELS: MDXH) is a molecular diagnostics company based in Irvine, CA and Liège Belgium and that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit http://www.mdxhealth.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.